Innovative Health App Transforms Care for Elderly Breast Cancer Patients

A groundbreaking clinical trial is underway, examining the efficacy of an innovative health application designed to manage cardiotoxicity in elderly women undergoing breast cancer treatment. Known as CARDIOCARE, this initiative aims to enhance the quality of life and health outcomes for patients over the age of 60 who are at risk of cardiac complications due to cancer therapies. The trial, which has successfully recruited more than 600 participants across Europe, is funded by the European Union’s Horizon 2020 research and innovation program and represents a significant advancement in patient-centered healthcare.

The need for such innovative solutions is underscored by the increasing number of elderly cancer patients, who often face a dual burden of cancer and cardiovascular risks. According to Dr. Georgia Karanasiou, a leading researcher on the CARDIOCARE project, “By integrating AI-driven risk prediction, real-time data, and patient-reported outcomes, we are transforming clinical care into a continuous, personalized, and proactive process.” This reflects a shift towards a more holistic approach to cancer treatment, recognizing the interplay between oncological and cardiovascular health.

The CARDIOCARE app utilizes a variety of data streams, including wearable sensors that monitor heart rate and mobility, as well as validated patient-reported outcomes. This data-driven approach allows for dynamic risk assessment and personalized care planning throughout the cancer care journey. Some participants will also benefit from additional features in the app that promote healthy behaviors, such as physical activity and cognitive exercises.

In addition to the development of real-time monitoring capabilities, CARDIOCARE seeks to empower patients by encouraging active participation in their healthcare journeys. Dr. Karanasiou noted, “We have been impressed by the willingness of elderly patients—many in their 70s—to engage with wearable technologies and mobile apps.” This is particularly noteworthy given the historical reluctance of this demographic to adopt new technologies.

The trial has garnered support from a diverse consortium of experts—including cardiologists, oncologists, psychologists, and bioinformaticians—from seven European countries, including Greece, Italy, and France. This multidisciplinary collaboration has been essential in developing AI-driven models that assist clinicians in personalizing care for elderly breast cancer patients.

While the integration of technology in healthcare is promising, challenges remain, particularly regarding the underrepresentation of elderly patients in clinical trials. Older adults often exhibit a higher risk of cardiotoxicity from cancer treatments, yet traditional clinical studies frequently overlook this demographic. As highlighted by the recent systematic review led by Brown et al. (2022) in the journal Cardio-Oncology, there is a critical need for evidence-based practices tailored specifically for older cancer patients.

As the CARDIOCARE trial progresses, its findings will be pivotal in shaping future clinical practices and policies. The research team plans to share insights at the upcoming European Society of Cardiology Cardio-Oncology Conference in Florence, Italy, on June 20, 2025. The outcomes of this trial could herald a new era in the management of cancer care for the elderly, ultimately leading to better health outcomes and improved quality of life for this vulnerable population.

In conclusion, the CARDIOCARE initiative exemplifies how innovative technology can address the complex needs of elderly cancer patients. By leveraging AI and real-time data, healthcare providers can offer more effective, personalized care that not only treats cancer but also safeguards the cardiovascular health of patients, thereby enhancing their overall well-being and resilience during treatment.